Related Experiment Video
Updated: May 29, 2025
28:13
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
33.2K
Atrial Fibrillation in End-Stage Heart Failure
Sebastian E Beyer1, Christian Sohns1, Philipp Sommer1
1Clinic for Electrophysiology, Herz- und Diabeteszentrum NRW, Ruhr Universität Bochum, Georgstr. 11, Bad Oeynhausen 32545, Germany.
Cardiac Electrophysiology Clinics
|February 1, 2025
Summary
End-stage heart failure (HF) management is complex, often involving atrial fibrillation. Catheter ablation shows promise in reducing HF symptoms and mortality, offering an alternative to medical treatments.
Area of Science:
- Cardiology
- Electrophysiology
Background:
- End-stage heart failure (HF) affects 1-10% of HF patients.
- HF frequently coexists with atrial fibrillation (AF) due to structural changes, altered hemodynamics, and neurohormonal activation.
- Treating HF with AF is challenging due to atrial remodeling, comorbidities, and high recurrence rates.
Purpose of the Study:
- To review the challenges and current treatment strategies for end-stage heart failure (HF) with coexistent atrial fibrillation (AF).
- To evaluate the efficacy of catheter ablation as a treatment option for HF patients with AF.
Main Methods:
- Literature review of studies investigating treatment options for end-stage heart failure (HF) and atrial fibrillation (AF).
- Analysis of data comparing medical rhythm control, rate control, and catheter ablation in HF patients with AF.
Main Results:
- Medical rhythm control offers no benefit over rate control for HF patients with AF.
- Catheter ablation may reduce HF symptomatology and all-cause mortality in these patients.
- AV nodal ablation is an option for refractory cases, but heart transplantation should not be delayed.
Conclusions:
- Catheter ablation presents a potential therapeutic advancement for managing end-stage heart failure (HF) with atrial fibrillation (AF).
- While AV nodal ablation exists for refractory cases, timely consideration for heart transplantation remains crucial.
Related Concept Videos
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:28Disturbances in Heart Rhythm
884
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
884
01:26Heart Failure Drugs: Inotropic Agents
505
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
505
01:26Imbalances in Cardiac Output
1.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
375
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
375
01:22Heart Failure Drugs: β-Blockers
311
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
311